From scientific content to scalable data
Embase and ScienceDirect: AI rights available for licensing
From scientific content to scalable data
Embase and ScienceDirect: AI rights available for licensing
Enable AI workflows with trusted Elsevier content—copyright cleared and reusable for consistent outputs, faster evidence generation and scalable reuse across the organization
Where integrated literature datasets can create value
Detect safety signals earlier—at scale and within your own systems
Integrate structured literature and full-text data directly into pharmacovigilance platforms to support automated signal detection, continuous monitoring, and regulatory reporting—without relying on manual searches or web-based tools.
Scale systematic literature reviews beyond manual and semi-automated workflows
Embed comprehensive literature datasets into review pipelines to support high-recall, reproducible evidence synthesis—reducing dependence on interactive tools and enabling consistent execution across teams.
Operationalize medical information workflows across teams
Deliver trusted scientific content directly into internal systems to support faster, more consistent evidence retrieval and response generation—without switching between tools or repeating searches.
Build more complete, data-driven views of KOLs
Incorporate publication and author data into internal analytics environments to enable scalable, cross-domain KOL identification— beyond what can be achieved through manual exploration or platform exports.
What you get with Elsevier datasets
Full-text datasets
Full-text access
to peer-reviewed scientific literature
~23M articles
across 3,000+ journals
High-impact content
from Cell Press, The Lancet, Clinics
Broad coverage
across therapeutic areas
Figures and images
from published articles
Embase datasets
Comprehensive biomedical literature,
including journals, conferences, and clinical trials
8,300+ journals and
5M conference abstracts
3,000 journals
not indexed in MEDLINE
500,000 clinical trials
from ClinicalTrials.gov
Preprints
from bioRxiv, medRxiv, and SSRN
Why license datasets vs. open or fragmented sources?
Why license datasets vs. open or fragmented sources?
- Full-text access, not just abstracts
- Broader and deeper coverage, including conferences and non-indexed journals
- Rights-cleared for commercial and internal use
- Structured for integration, enabling systematic use across workflows
- Enables operational scalability, consistency and reproducibility
Dataset subscriptions enable organizations to integrate Elsevier content directly into internal systems and workflows—supporting repeatable, scalable use across teams. Unlike web-based subscriptions designed for individual access and reading, datasets are built for system-level integration, automation, and reuse across enterprise environments.
“By aligning technical safeguards, licensing models and legal frameworks from the start, we’re proving that AI can be implemented in a way that meets the needs of users while protecting the rights of content owners. It’s not about compromise — it’s about designing AI systems that create lasting value for all stakeholders.”
– Dr Miena Amiri, CEO, AVAYL
Get started
Connect with our data experts to explore how Embase and full-text datasets or an AI reuse rights license can support your workflows and enable you to use Elsevier content with full copyright compliance.
Contact us: [email protected]